Does Rallies show Form 4 insider transactions for RVMD?

Yes. Rallies tracks RVMD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is RVMD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RVMD. It does not provide personalized investment advice.

RVMD (Revolution Medicines, Inc. Common Stock) Stock Analysis - Insider Trades

Revolution Medicines, Inc. Common Stock (RVMD) is a publicly traded Healthcare sector company. As of May 20, 2026, RVMD trades at $150.91 with a market cap of $30.69B and a P/E ratio of -24.94. RVMD moved +1.94% today. Year to date, RVMD is +91.92%; over the trailing twelve months it is +271.46%. Its 52-week range spans $29.17 to $155.70. Analyst consensus is strong buy with an average price target of $176.95. Rallies surfaces RVMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading RVMD stock inside the company?

Recent RVMD insider activity includes Mancini Anthony sold 1.67K, Mancini Anthony sold 1.05K, Mancini Anthony sold 400, GOLDSMITH MARK A sold 120.00K, and Mancini Anthony sold 1.80K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

RVMD Key Metrics

Key financial metrics for RVMD
Metric	Value
Price	$150.91
Market Cap	$30.69B
P/E Ratio	-24.94
EPS	$-5.95
Dividend Yield	0.00%
52-Week High	$155.70
52-Week Low	$29.17
Volume	2.04M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-1.13B
Gross Margin	0.00%

Recent RVMD Insider Trades

Mancini Anthony sold 1.67K (~$220.01K) on Apr 27, 2026.
Mancini Anthony sold 1.05K (~$139.39K) on Apr 27, 2026.
Mancini Anthony sold 400 (~$53.73K) on Apr 27, 2026.
GOLDSMITH MARK A sold 120.00K (~$18.01M) on Apr 15, 2026.
Mancini Anthony sold 1.80K (~$167.80K) on Mar 25, 2026.

Latest RVMD News

RVMD slides after Needham target cut tied to raised 2026 cost guidance — May 7, 2026
Revolution Medicines’ Daraxonrasib Phase 1/2 Data Show Durable Responses, OS Benefit — May 6, 2026
RVMD climbs as FDA clears expanded-access path for pancreatic cancer drug daraxonrasib — May 4, 2026
RVMD slips as investors price in $2.2B equity-and-convert financing overhang — May 1, 2026
Revolution Medicines slides as April $2.2B financing overhang persists — Apr 29, 2026

RVMD Analyst Consensus

20 analysts cover RVMD: 0 strong buy, 20 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $176.95.

Common questions about RVMD

Who is trading RVMD stock inside the company?: Recent RVMD insider activity includes Mancini Anthony sold 1.67K, Mancini Anthony sold 1.05K, Mancini Anthony sold 400, GOLDSMITH MARK A sold 120.00K, and Mancini Anthony sold 1.80K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for RVMD?: Yes. Rallies tracks RVMD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is RVMD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RVMD. It does not provide personalized investment advice.